

Table 50: MID for continuous outcomes (0.5 x SD): Central nervous system stimulants versus placebo

Outcomes	MID
Quality of Life: SF36 physical total Scale from: 0 to 100.	5.42
Quality of Life: SF36 mental total Scale from: 0 to 100.	6.53
Quality of Life: SF36 vitality Scale from: 0 to 100.	2.05
Quality of Life: SF36 physical role limitation Scale from: 0 to 100.	4.5
Quality of Life: SF36 physical function Scale from: 0 to 100.	3.85
Quality of Life: SF36 mental health Scale from: 0 to 100.	1.85
Quality of Life: SF36 emotional role limitation Scale from: 0 to 100.	3.8
Quality of Life: SF36 pain Scale from: 0 to 100.	4.4
Quality of life: SF36 social Scale from: 0 to 100.	4
Quality of life: SF36 general health Scale from: 0 to 100.	2.5
Fatigue: Checklist Individual Strength (CIS) total score Scale from: 20 to 140.	9.24
Fatigue: Fatigue Severity Scale Scale from: 9 to 63.	2.24
Fatigue: Chalder Physical Fatigue scale Scale from: 0 to 21.	0.6

Outcomes	MID
Fatigue: Chalder Mental Fatigue scale Scale from: 0 to 12.	0.35
Sleep quality: sleep latency (time taken to fall asleep in mins)	3.99
Psychological status: HADS anxiety Scale from: 0 to 21.	2.2
Psychological status: HADS depression Scale from: 0 to 21.	1.95
Psychological status: Hamilton Anxiety Scale	4.14
Cognitive function: Behaviour Rating Inventory of Executive Function (BRIEF), global executive composite Scale from: not reported.	3.63
Pain: McGill pain Questionnaire Scale from: 0 to 78	4.77
Symptom scales: Clinical global improvement Scale from: not reported.	0.46